Literature DB >> 16374008

Effect of anti-OprF-OprI immunoglobulin on APACHE II score in a porcine two-hit model of hemorrhagic shock/resuscitation and pseudomonas aeruginosa sepsis.

J Haberstroh1, H E Gilleland, B-U von Specht.   

Abstract

BACKGROUND: Up to now, randomized clinical trials of treatment of bacterial sepsis with immunoglobulins show conflicting results. This paper investigates the effect of prophylactic immunization with anti-OprF-OprI antiserum on the APACHE II score in a clinically relevant two-hit model of hemorrhagic shock/resuscitation followed by Pseudomonas aeruginosa sepsis in pigs.
METHODS: Twenty-three German Landrace-Hybrid pigs underwent chronic implantation of vascular catheters (internal and external jugular vein, carotic and pulmonary artery), hemorrhagic shock (mean blood loss 40% of estimated blood volume) for 45 min, followed by resuscitation with crystalloid, colloid, and shed blood. Randomization was to a control group (no immunization, n=6), an F-I group (50 mg/kg i.p. anti-OprF-OprI immunoglobulin, n=6), an S group (50 mg/kg i.p. unspecific porcine immunoglobulins, n=6), and a PS group (50 mg/kg i.p. immunoglobulin against the antigens of heat-killed P. aeruginosa, n=5). After at least 18 h for recovery from anesthesia, the pigs underwent a continuous intravenous infusion of P. aeruginosa for 48 h. Thereafter, the animals were monitored for another 48 h and then dissected.
RESULTS: The APACHE II score significantly increased from baseline value in all groups during bacterial challenge. However, there were no between-group differences in APACHE II score. In contrast, pigs of the F-I and PS groups showed significant lower lung concentrations of P. aeruginosa (p<0.05 vs. control group) at autopsy.
CONCLUSION: These experimental data suggest that under comparable clinical conditions, a prophylactic immunization with anti-OprF-OprI immunoglobulin would not have an overall benefit to patients with P. aeruginosa sepsis. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16374008     DOI: 10.1159/000089232

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  4 in total

1.  Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.

Authors:  Feng Yang; Jiang Gu; Liuyang Yang; Chen Gao; Haiming Jing; Ying Wang; Hao Zeng; Quanming Zou; Fenglin Lv; Jinyong Zhang
Journal:  Sci Rep       Date:  2017-06-21       Impact factor: 4.379

2.  Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB/c Mouse Model.

Authors:  Mohammad Hadi Fakoor; Seyed Latif Mousavi Gargari; Parviz Owlia; Azar Sabokbar
Journal:  Infect Drug Resist       Date:  2020-06-09       Impact factor: 4.003

3.  Vaccination of mice with hybrid protein containing Exotoxin S and PcrV with adjuvants alum and MPL protects Pseudomonas aeruginosa infections.

Authors:  Mohammad Reza Asadi Karam; Farzad Badmasti; Khadijeh Ahmadi; Mehri Habibi
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

4.  Cell-free DNA increase over first 48 hours in emergency intensive care unit predicts fatal outcome in patients with shock.

Authors:  Dun Ling Xia; Hong Zhang; Qing Li Luo; A Fang Zhang; Li Xin Zhu
Journal:  J Int Med Res       Date:  2016-09-27       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.